Here are five points:
1. B. Riley researchers estimate Mazor will see second quarter 2018 earnings of $0.13 EPS; third quarter 2018 earnings of $0.12 EPS; and fourth quarter 2018 earnings of $0.07 EPS.
2. The firm has a “neutral” rating on Mazor with a $25 price objective.
3. Mazor has a 52-week low of $9.16 and 52-week high of $26.55.
4. The company’s 50-day moving average is $22.62, with a 200-day moving average of $22.74.
5. Mazor’s market capitalization is $535.76 million.
More articles on devices:
SeaSpine revenue drops 3.2% to $128.9M in 2016: 8 key notes
Image-guided orthopedic surgery market to grow at 7% CAGR through 2022: 5 observations
Implanet earns French patent to protect JAZZ Lock: 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
